Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients

European Journal of Medical Research

Bernhard Homey³  Andreas Wollenberg¹  Christiane Matuschek²  Edwin Bölke²  Wilfried Budach²  Laura Maximiliane Ehmann¹  Sonja Hetzer³  Holger Schrumpf³  Bettina Alexandra Buhren³  Tatiana Eames¹  Stephan Meller³  Peter Arne Gerber³ 

[1] Department of Dermatology, Ludwig-Maximilians-University of Munich, Frauenlobstraße 9-11 & Thalkirchner Straße 48, 80539 Munich, Germany;Department of Radiation Oncology, University of Duesseldorf, Medical Faculty, Moorenstrasse 5, D-40225 Duesseldorf, Germany;Department of Dermatology, University of Duesseldorf, Medical Faculty, Moorenstrasse 5, D-40225 Duesseldorf, Germany

关键词: gefitinib;    panitumumab;    cetuximab;    erlotinib;    papulopustular exanthema;    rash;    EGFR;   

Others  :  820323
DOI  :  10.1186/2047-783X-17-4

 received in 2011-11-17, accepted in 2012-02-23,  发布年份 2012

【 摘 要 】

Background

In recent years inhibitors directed against the epidermal growth factor receptor (EGFR) have evolved as effective targeting cancer drugs. Characteristic papulopustular exanthemas, often described as acneiform rashes, are the most frequent adverse effect associated with this class of novel cancer drugs and develop in > 90% of patients. Notably, the rash may significantly compromise the patients' quality of life, thereby potentially leading to incompliance as well as dose reduction or even termination of the anti-EGFR therapy. Yet, an effective dermatologic management of cutaneous adverse effects can be achieved. Whereas various case reports, case series or expert opinions on the management of EGFR-inhibitor (EGFRI) induced rashes have been published, data on systematic management studies are sparse.

Methods

Here, we present a retrospective, uncontrolled, comparative study in 49 patients on three established regimens for the management of EGFRI-associated rashes.

Results

Strikingly, patients' rash severity improved significantly over three weeks of treatment with topical mometason furoate cream, topical prednicarbate cream plus nadifloxacin cream, as well as topical prednicarbate cream plus nadifloxacin cream plus systemic isotretinoin.

Conclusions

In summary our results demonstrate that EGFRI-associated rashes can be effectively managed by specific dermatologic interventions. Whereas mild to moderate rashes should be treated with basic measures in combination with topical glucocorticosteroids or combined regiments using glucocorticosteroids and antiseptics/antibiotics, more severe or therapy-resistant rashes are likely to respond with the addition of systemic retinoids.

【 授权许可】

   
2012 Gerber et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Ciardiello F, Tortora G: EGFR antagonists in cancer treatment. N Engl J Med 2008, 358:1160-1174.
• [2]Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
• [3]Gerber PA, Buhren BA, Kurle S, Homey B: [Therapy with epidermal growth factor receptor inhibitors. Clinical spectrum of cutaneous adverse effects]. Hautarzt 2010, 61:654-661.
• [4]Gerber PA, Buhren BA, Steinhoff M, Homey B: Rosacea: the cytokine and chemokine network. J Investig Dermatol Symp Proc 2011, 15:40-47.
• [5]Gutzmer R, Becker JC, Enk A, Garbe C, Hauschild A, Leverkus M, Reimer G, Treudler R, Tsianakas A, Ulrich C, Wollenberg A, Homey B: Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician. J Dtsch Dermatol Ges 2011, 9:195-203.
• [6]Potthoff K, Hofheinz R, Hassel JC, Volkenandt M, Lordick F, Hartmann JT, Karthaus M, Riess H, Lipp HP, Hauschild A, Trarbach T, Wollenberg A: Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol 2011, 22:524-535.
• [7]Eames T, Kroth J, Flaig MJ, Ruzicka T, Wollenberg A: Perifollicular xanthomas associated with epidermal growth factor receptor inhibitor therapy. Acta Derm Venereol 2010, 90:202-203.
• [8]Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, Bonomi P: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004, 22:3238-3247.
• [9]Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ: Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007, 13:3913-3921.
• [10]Eilers RE Jr, Gandhi M, Patel JD, Mulcahy MF, Agulnik M, Hensing T, Lacouture ME: Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst 2010, 102:47-53.
• [11]Forton F, Seys B: Density of Demodex folliculorum in rosacea: a case-control study using standardized skin-surface biopsy. Br J Dermatol 1993, 128:650-659.
• [12]Gerber PA, Buhren BA, Cevikbas F, Bolke E, Steinhoff M, Homey B: Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor-induced pruritus. J Am Acad Dermatol 2010, 63:163-165.
• [13]Gerber PA, Buhren BA, Homey B: More on aprepitant for erlotinib-induced pruritus. N Engl J Med 2011, 364:486-487.
• [14]Gerber PA, Homey B: Images in clinical medicine. Erlotinib-induced hair alterations. N Engl J Med 2008, 358:1175.
• [15]Shah NT, Kris MG, Pao W, Tyson LB, Pizzo BM, Heinemann MH, Ben-Porat L, Sachs DL, Heelan RT, Miller VA: Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 2005, 23:165-174.
• [16]Wollenberg A, Kroth J, Hauschild A, Dirschka T: Cutaneous side effects of EGFR inhibitors-appearance and management. Dtsch Med Wochenschr 2010, 135:149-154.
• [17]Bernier J, Russi EG, Homey B, Merlano MC, Mesia R, Peyrade F, Budach W: Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines. Ann Oncol 2011, 22:2191-2200.
• [18]Bolke E, Gerber PA, Lammering G, Peiper M, Muller-Homey A, Pape H, Giro C, Matuschek C, Bruch-Gerharz D, Hoffmann TK, Gripp S, Homey B, Budach W: Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab. Strahlenther Onkol 2008, 184:105-110.
• [19]Budach W, Bolke E, Homey B: Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 2007, 357:514-515.
• [20]Sartor CI: Mechanisms of disease: Radiosensitization by epidermal growth factor receptor inhibitors. Nat Clin Pract Oncol 2004, 1:80-87.
• [21]Gerber PA, Enderlein E, Homey B, Muller A, Boelke E, Budach W: Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects. J Clin Oncol 2007, 25:4697-4698. author reply 4698-4699
• [22]Bernier J, Bonner J, Vermorken JB, Bensadoun RJ, Dummer R, Giralt J, Kornek G, Hartley A, Mesia R, Robert C, Segaert S, Ang KK: Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008, 19:142-149.
• [23]Gutzmer R, Werfel T, Mao R, Kapp A, Elsner J: Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol 2005, 153:849-851.
• [24]Katzer K, Tietze J, Klein E, Heinemann V, Ruzicka T, Wollenberg A: Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab - A report of 29 patients. Eur J Dermatol 2010, 20:82-84.
• [25]Wollenberg A, Moosmann N, Kroth J, Heinemann V, Klein E: Therapy of severe cetuximab-induced acneiform eruptions with oral retinoid, topical antibiotic and topical corticosteroid. Hautarzt 2007, 58:615-618.
• [26]Wollenberg A, Moosmann N, Klein E, Katzer K: A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition. Exp Dermatol 2008, 17:790-792.
• [27]Tokumaru S, Sayama K, Shirakata Y, Komatsuzawa H, Ouhara K, Hanakawa Y, Yahata Y, Dai X, Tohyama M, Nagai H, Yang L, Higashiyama S, Yoshimura A, Sugai M, Hashimoto K: Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37. J Immunol 2005, 175:4662-4668.
• [28]Prakash A, Benfield P: Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Drugs 1998, 55:145-163.
• [29]Powell FC: Clinical practice. Rosacea. N Engl J Med 2005, 352:793-803.
• [30]Schoepe S, Schacke H, May E, Asadullah K: Glucocorticoid therapy-induced skin atrophy. Exp Dermatol 2006, 15:406-420.
• [31]Marquardt C, Matuschek E, Bolke E, Gerber PA, Peiper M, J VS-K, Buhren BA, van Griensven M, Budach W, Hassan M, Kukova G, Mota R, Hofer D, Orth K, Fleischmann W: Evaluation of the tissue toxicity of antiseptics by the hen's egg test on the chorioallantoic membrane (HETCAM). Eur J Med Res 2010, 15:204-209. BioMed Central Full Text
• [32]Kujath P, Kujath C: Complicated skin, skin structure and soft tissue infections - are we threatened by multi-resistant pathogens? Eur J Med Res 2010, 15:544-553.
• [33]Gerber PA, Enderlein E, Homey B: The Koebner-phenomenon in epidermal growth factor receptor inhibitor-induced cutaneous adverse effects. J Clin Oncol 2008, 26:2790-2792.
• [34]Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, Kemeny NE, Halpern AC: Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007, 25:5390-5396.
• [35]Wilke MH: Multiresistant bacteria and current therapy - the economical side of the story. Eur J Med Res 2010, 15:571-576. BioMed Central Full Text
• [36]Abdelmohsen K, Gerber PA, von Montfort C, Sies H, Klotz LO: Epidermal growth factor receptor is a common mediator of quinone-induced signaling leading to phosphorylation of connexin-43: role of glutathione and tyrosine phosphatases. J Biol Chem 2003, 278:38360-38367.
• [37]Abdelmohsen K, von Montfort C, Stuhlmann D, Gerber PA, Decking UK, Sies H, Klotz LO: Doxorubicin induces EGF receptor-dependent downregulation of gap junctional intercellular communication in rat liver epithelial cells. Biol Chem 2005, 386:217-223.
• [38]Klotz LO, Patak P, Ale-Agha N, Buchczyk DP, Abdelmohsen K, Gerber PA, von Montfort C, Sies H: 2-Methyl-1,4-naphthoquinone, vitamin K(3), decreases gap-junctional intercellular communication via activation of the epidermal growth factor receptor/extracellular signal-regulated kinase cascade. Cancer Res 2002, 62:4922-4928.
• [39]Li T, Perez-Soler R: Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009, 4:107-119.